Other studies have also shown that CREPT is overexpressed in CRC, contributes to tumor progression and cell proliferation, is positively correlated with the efficacy of 5-FU treatment, and can serve as a valuable prognostic biomarker for CRC patients [23]. This evidence concerns the gene RPRD1B and colorectal carcinoma.